MarketCap
Facebook
X
Telegram
Epizyme General and Administrative Expenses | EPZM
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 134 M | 125 M | 23.5 M | 12.2 M | 37.2 M | 28.4 M | 23.9 M | 20.9 M | 14 M | 7.51 M | 5 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 134 M | 5 M | 39.2 M |
Quarterly General and Administrative Expenses Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 24.1 M | 27.2 M | - | 32.8 M | 33.9 M | 36.4 M | 35 M | 30.6 M | 32.7 M | 26.9 M | 23.5 M | 17.1 M | 15.7 M | 12 M | 12.2 M | 11.5 M | 10.9 M | 9.36 M | 8.43 M | 9.31 M | 11.2 M | 8.27 M | 7.58 M | 7.52 M | 7.42 M | 5.85 M | 6.02 M | 6.68 M | 5.97 M | 5.24 M | 4.94 M | 5.67 M | 5.31 M | 4.96 M | 4.38 M | 3.59 M | 3.08 M | 3 M | 2.33 M | 1.63 M | 1.64 M | 1.91 M | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 36.4 M | 1.63 M | 12.8 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
IDEAYA Biosciences
IDYA
|
63.3 M | $ 33.2 | -4.35 % | $ 2.94 B |  USA |
 |
InflaRx N.V.
IFRX
|
13.5 M | $ 1.57 | 0.32 % | $ 106 M |  Germany |
 |
Immutep Limited
IMMP
|
8.64 M | $ 3.07 | -4.06 % | $ 4.47 B |  Australia |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
1.59 M | $ 1.89 | -6.44 % | $ 1.27 B |  Israel |
 |
Zoetis
ZTS
|
2.38 B | $ 80.89 | -0.17 % | $ 35.9 B | USA |
 |
Kala Pharmaceuticals
KALA
|
23.6 M | $ 0.19 | -1.95 % | $ 1.55 M | USA |
 |
Mereo BioPharma Group plc
MREO
|
21.2 M | $ 0.28 | -1.99 % | $ 223 M |  Britain |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
196 M | $ 73.0 | -4.87 % | $ 5.42 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
105 M | $ 0.48 | -6.34 % | $ 5.25 K | USA |
 |
MediciNova
MNOV
|
6.16 M | $ 1.41 | 1.44 % | $ 69.2 M | USA |
 |
Seres Therapeutics
MCRB
|
39.2 M | $ 2.01 | -3.83 % | $ 17.8 M | USA |
 |
MediWound Ltd.
MDWD
|
5.35 M | $ 12.1 | 0.83 % | $ 329 M | Israel |
 |
SELLAS Life Sciences Group
SLS
|
12.3 M | $ 11.35 | -1.69 % | $ 1.24 B | USA |
 |
Precigen
PGEN
|
70.1 M | $ 6.05 | -2.34 % | $ 1.89 B | USA |
 |
PolyPid Ltd.
PYPD
|
7.18 M | $ 5.3 | 0.95 % | $ 86.7 M | Israel |
 |
Rocket Pharmaceuticals
RCKT
|
86.5 M | $ 2.27 | -0.87 % | $ 252 M | USA |
 |
Avidity Biosciences
RNA
|
206 M | $ 8.04 | -1.93 % | $ 1.11 B | USA |
 |
Summit Therapeutics
SMMT
|
557 M | $ 14.5 | -6.3 % | $ 10.8 B | Britain |
 |
Celsion Corporation
CLSN
|
6.87 M | - | -6.63 % | $ 13.9 M | USA |
 |
I-Mab
IMAB
|
453 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
5.49 M | - | -13.47 % | $ 169 M | France |
 |
Scholar Rock Holding Corporation
SRRK
|
176 M | $ 41.71 | 0.52 % | $ 4.78 B | USA |
 |
CureVac N.V.
CVAC
|
69.7 M | - | - | $ 867 M | Germany |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
24.5 M | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
224 M | - | - | $ 4.9 B | Britain |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | Britain |
 |
MorphoSys AG
MOR
|
65.8 M | - | 2.43 % | $ 254 M | Germany |
 |
Affimed N.V.
AFMD
|
24.7 M | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
7.25 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
10.5 M | - | - | $ 12.5 M |  Belgium |
 |
Gracell Biotechnologies
GRCL
|
139 M | - | - | $ 3.37 B | China |
 |
Galapagos NV
GLPG
|
147 M | - | - | $ 1.83 B | Belgium |
 |
Tiziana Life Sciences PLC
TLSA
|
286 K | $ 0.88 | -7.06 % | $ 93.9 M | Britain |
 |
Teligent, Inc.
TLGT
|
23.4 M | - | -13.85 % | $ 16.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
60.2 M | - | - | $ 2.91 B | USA |
 |
Aphria Inc.
APHA
|
164 M | - | -0.45 % | $ 4.87 B |  Canada |
 |
Aerpio Pharmaceuticals, Inc.
ARPO
|
8.76 M | - | -0.90 % | $ 104 M | USA |
 |
Chiasma, Inc.
CHMA
|
39.6 M | - | -6.00 % | $ 238 M | USA |
 |
Adamas Pharmaceuticals, Inc.
ADMS
|
107 M | - | - | $ 376 M | USA |
 |
Cellect Biotechnology Ltd.
APOP
|
10.2 M | - | 0.38 % | $ 12.9 M | Israel |
 |
AzurRx BioPharma, Inc.
AZRX
|
7.29 M | - | 2.07 % | $ 34.4 M | USA |
 |
Cerecor Inc.
CERC
|
17.4 M | - | -1.68 % | $ 283 M | USA |
 |
Constellation Pharmaceuticals, Inc.
CNST
|
29.3 M | - | - | $ 1.63 B | USA |
 |
Auris Medical Holding Ltd.
EARS
|
2.6 M | - | -1.77 % | $ 39.2 M |  Bermuda |
 |
Dicerna Pharmaceuticals, Inc.
DRNA
|
72.1 M | - | 0.34 % | $ 2.98 B | USA |
 |
ERYTECH Pharma S.A.
ERYP
|
13.9 M | - | 1.3 % | $ 27.7 M | France |
 |
GW Pharmaceuticals plc
GWPH
|
336 M | - | - | $ 6.81 B | Britain |